In the News
K&S Represents AbbVie in False Claims Act Dispute Involving 340B Drug Pricing Program
July 1, 2026

K&S counsels AbbVie and its affiliates in a False Claims Act dispute before a California federal court.
 
 Third-party coverage:

Big Pharma Cos. Want 340B Drug Price FCA Suit Tossed (Law360)

Explore King & Spalding
a blue and green background
Capabilities
Life Sciences & Healthcare
a blue and green background
Capabilities
False Claims Act, Qui Tam & Whistleblower Investigations